CME (CME Group) Growth Rank: 9 (As of Aug. 01, 2026) — 13% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CME CME Group Inc CME
78 GF Score
Price $267.79
GF Value $271.74
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is CME Group Growth Rank?

CME Group CME +0.21% 78 Growth Rank is 9 as of Aug. 01, 2026, which is 13% above its 10-year median of 8.00. GuruFocus rates CME with a GF Score™ of 78/100 and a GF Value™ of $271.74 (Fairly Valued). The stock has 3 warning signs investors should review.

CME Group has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CME vs ICE, MCO, SPGI: Growth Rank Comparison

For the Financial Data & Stock Exchanges subindustry, CME Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CME Group Growth Rank vs Capital Markets Industry

For the Capital Markets industry and Financial Services sector, CME Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where CME Group's Growth Rank falls into.


CME
78GF Score
CME Group Inc CME
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
CME Group (CME) has a Growth Rank of 9 as of Aug. 01, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CME Group and its competitors. This is 13% above median its historical median of 8.00. Over the past decade, CME Group's Growth Rank has ranged from 5.00 to 10.00.
Is CME Group's Growth Rank too high?
CME Group's current Growth Rank of 9 is 13% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, CME Group has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CME Group's Growth Rank compare to ICE and MCO?
CME Group's Growth Rank of 9 can be compared against companies in the Capital Markets industry. Historically, CME Group's own Growth Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Capital Markets company?
A good Growth Rank depends on the Capital Markets industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CME Group and its competitors. CME Group's current Growth Rank is 9, which is 13% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Fairly Valued. The stock's GF Value™ is $271.74, compared to a current price of $267.79 — trading 1.5% below its estimated fair value. The current Growth Rank is 9, which is 13% above median its 10-year median of 8.00. CME Group's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For CME Group (CME), the current Growth Rank is 9 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CME Group (CME) Overvalued in 2026?

Based on GuruFocus' analysis, CME Group stock appears to be undervalued. The current stock price of $267.79 is trading 1.5% below its estimated GF Value™ of $271.74. GuruFocus considers CME Group to be Fairly Valued.

Key valuation signals for CME:

  • Growth Rank: 9 (13% above median its 10-year median of 8.00)
  • GF Value™: $271.74 vs. price of $267.79 (1.5% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CME Group Business Description

Address 20 South Wacker Drive, Chicago, IL, USA, 60606
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
78GF Score

Get the complete analysis for CME

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$267.79
Price
$271.74
GF Value